Company: CI
Filing Date: 2025-03-14
Form Type: DEF 14A
Source: 0001739940-25-000015
Chunk: 67

Company: Cigna Group
Filing Date: 2025-03-14
Form: DEF 14A
Chunk 67
---
 patients, and the enrollment of approximately 8 million lives in EncircleRx, a new solution for managing GLP-1 medications for weight loss and diabetes. Client and patient NPS results were strong, with positive feedback from clients and brokers on partnership, collaboration and responsiveness. Under Mr. Palmer’s leadership, the organization made progress in aligning corporate development with business unit priorities and effectively executed a number of acquisitions and related integration activities, including with respect to the establishment of our comprehensive fertility pharmacy solution. As a result of his contributions in 2024, Mr. Palmer was awarded a 2024 EIP payment of $1,840,000, or 92% of his target.

| 68 |     | The Cigna Group| 2025 Notice of Annual Meeting of Shareholders and Proxy Statement |

| COMPENSATION MATTERS |

Annual Incentive Plan Changes for 2025

For the 2025 EIP, to motivate and drive execution of the Company’s business strategy and the achievement of enterprise results, the Committee approved the following performance measures and weightings.

| Measure                         |     | Alignment with Business Strategy                                                                                                                                                                                                                                                                                                                                                               |     | Weighting |
| Adjusted Income from Operations |     | Reinforces the importance of sustained profitable growth across the enterprise by rewarding financial performance that reflects the underlying results of operations of the Company’s businesses.                                                                                                                                                                                              |     | 50%       |
| Growth                          |     | Emphasizes: (1) retaining existing clients; (2) expanding our current client relationships through strong service and comprehensive whole-health offerings; and (3) earning the right to provide value to new clients to fuel our growth. Growth is measured quantitatively by adjusted revenues (15% of EIP weighting) and growth in specialty pharmacy prescriptions (10% of EIP weighting). |     | 25%       |
| Strategic Priorities            |     | Advances the interests of our customers, patients, clients, other stakeholders, and ultimately, our shareholders by positioning us for long-term growth through the focus on progress in areas that support our mission, values, and business strategy.                                                                                                                                        |     | 25%       |

For 2025, the areas of focus for the strategic priorities will be as follows:

| Strategic Priority Areas of Focus |     | Relevance to Business Strategy                                                                                                                                                                                                                  |     | Weighting |     | Quantitative Measurements                                                                                                                                       |
| Customer and Patient Satisfaction |     | As a mission-based company, we know that higher satisfaction among our customers and patients